Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02550119 · ClinicalTrials.gov registry record · NA
Dolasetron Mesylate and Dexamethasone With or Without Aprepitant in Preventing Nausea and Vomiting in Patients Undergoing Oxaliplatin-Containing Chemotherapy for Gastrointestinal Malignancy
A NA study, sponsored by University of Southern California.
- Terminated
- Registry status
- NA
- Development phase
- 19
- Enrollment target
NCT02550119 is a NA study that was terminated before completion, run by University of Southern California. The registered enrollment target is 19 participants.
The verdict
NCT02550119, a NA study, was terminated before completion, sponsored by University of Southern California.
- TERMINATED
- Registry status
- NA
- Development phase
- 19 participants
- Enrollment target
Study Summary
This randomized pilot clinical trial dolasetron mesylate and dexamethasone with or without aprepitant in preventing nausea and vomiting in patients undergoing oxaliplatin-containing chemotherapy for gastrointestinal malignancy. Antiemetic drugs may help lessen or prevent nausea and vomiting in patients treated with chemotherapy. It is not yet known whether giving aprepitant together with dolasetron mesylate and dexamethasone is more effective than dolasetron mesylate and dexamethasone alone in preventing nausea and vomiting.
Interventions
- DRUG Placebo
- DRUG Dexamethasone
- DRUG Aprepitant
- DRUG Dolasetron Mesylate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2006-04-19 |
| Est. Completion | 2010-04-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02550119
The ClinicalTrials.gov registry entry for NCT02550119 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Southern California, which has 617 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT02550119 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02550119 about?
NCT02550119 is a clinical study titled "Dolasetron Mesylate and Dexamethasone With or Without Aprepitant in Preventing Nausea and Vomiting in Patients Undergoing Oxaliplatin-Containing Chemotherapy for Gastrointestinal Malignancy". This randomized pilot clinical trial dolasetron mesylate and dexamethasone with or without aprepitant in preventing nausea and vomiting in patients undergoing oxaliplatin-containing chemotherapy for gastrointestinal malignancy. Antiemetic drugs may help lessen or prevent nausea and vomiting in patie...
What is the current status of trial NCT02550119?
This trial is currently terminated. It is a NA study. The enrollment target is 19 participants. The study started on 2006-04-19. Estimated completion is 2010-04-01.
What interventions are being tested in trial NCT02550119?
The interventions under investigation include: Placebo (DRUG), Dexamethasone (DRUG), Aprepitant (DRUG), Dolasetron Mesylate (DRUG).
Who is sponsoring clinical trial NCT02550119?
This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.